When is Nabla the better choice?

The only positive randomized controlled result in this category, a 9.5 percent reduction in time in note against control and the only arm to meet its primary endpoint. The widest record system footprint in the category, more than fifteen platforms named, which suits a mixed European and international estate. The data lifecycle is published to the point of backup expiry, with audio not stored and no training on user data.

When is TORTUS the better choice?

It filters before the clinician rather than after, removing unsupported statements before they are seen, and publishes the rate at which that filter works alongside a peer reviewed reduction in major hallucinations. The evidence is prospective, multi site, publicly funded and independently evaluated across nine clinical sites and more than seventeen thousand patients. Accent performance was tested by the deploying hospital rather than by the vendor, which is the difference between naming a risk and measuring it.

Nabla vs TORTUS

Last VerifiedAugust 4, 2026

Verdict

The two European scribes with real evidence behind them, and they proved different things. Nabla holds the only positive randomized controlled result in this category, reducing time in note by 9.5 percent in a trial it did not run, and publishes its data lifecycle down to backup expiry across the widest record system footprint here. TORTUS ran the deeper deployment study, nine clinical sites and more than seventeen thousand patients with public funding and independent evaluation, and it does something Nabla does not: filters unsupported statements before the clinician sees them and publishes how well that filter works. For a National Health Service organisation TORTUS is embedded in the estate and hard to beat. For a European or international system running several record platforms, Nabla travels better and has the efficiency result nobody else can claim.

Select Nabla if

The only positive randomized controlled result in this category, a 9.5 percent reduction in time in note against control and the only arm to meet its primary endpoint.
The widest record system footprint in the category, more than fifteen platforms named, which suits a mixed European and international estate.
The data lifecycle is published to the point of backup expiry, with audio not stored and no training on user data.

Select TORTUS if

It filters before the clinician rather than after, removing unsupported statements before they are seen, and publishes the rate at which that filter works alongside a peer reviewed reduction in major hallucinations.
The evidence is prospective, multi site, publicly funded and independently evaluated across nine clinical sites and more than seventeen thousand patients.
Accent performance was tested by the deploying hospital rather than by the vendor, which is the difference between naming a risk and measuring it.

Attribute Matrix

Side by Side

Axis	N Nabla	T TORTUS
AI Centrality
Autonomy and Oversight Model
Model and Technology Transparency
Clinical and Operational Evidence
AI Safety and PHI Stewardship
HIPAA and BAA Posture
Security Certifications and Trust Center
FDA and Regulatory Status
AI Governance and Bias Disclosure
EHR and Interoperability Depth
Deployment Model and Data Residency
Commercial Transparency
Setting and Specialty Coverage

Keep Comparing

Related comparisons

Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Ambient Scribes page.

Abridge vs Nabla→Ambience Healthcare vs Nabla→Commure vs Nabla→Corti vs Nabla→Corti vs TORTUS→DeepScribe vs Nabla→Doximity Scribe vs Nabla→Freed vs Nabla→Heidi Health vs Nabla→Heidi Health vs TORTUS→Microsoft Dragon Copilot vs Nabla→Microsoft Dragon Copilot vs TORTUS→

Disclosure

Neither vendor is a straightforward purchase outside its home region. TORTUS is deep in the National Health Service estate and unevidenced elsewhere, asserts alignment with United States health privacy rules through third party listings with no agreement template located, and holds a self certified device registration rather than a reviewed clearance.

Nabla's free tier is reported not to include a business associate agreement and its published pricing was withdrawn during 2026 in favour of a sales motion. Neither publishes a subgroup analysis beyond the hospital led accent testing noted above.